3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
8
Prostatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
HER2-positive Breast Cancer
2
Endometrial Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
HR+/HER2+ Early Breast Cancer
1
Glioma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Specimen Handling
7
Magnetic Resonance Spectroscopy
7
Cisplatin
6
pembrolizumab
4
durvalumab
4
Platinum
4
Carboplatin
4
1,2-diaminocyclohexaneplatinum II citrate
4
cemiplimab
3
Radiation
3
Paclitaxel
3
Cetuximab
3
Biopsy
3
(225)Ac-DOTA-c(RGDyK)
3
cabozantinib
2
atezolizumab
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Pemetrexed
2
Nivolumab
2
Immunoglobulin G
2
Docetaxel
2
Disulfides
2
ALT-803
2
130-nm albumin-bound paclitaxel
2
zipalertinib
1
repotrectinib
1
poly ICLC
1
ipatasertib
1
fludarabine phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma
×
pertuzumab
×
30 days
×
Clear all
No trials found.